PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21882223-7	2012	The functional expression of osteoblast in alkaline phosphatase (ALP) activity was significantly decreased by CoCl(2) and inhibited when treated with DFO.	Deferoxamine	150-153	alkaline phosphatase, placental	Homo sapiens	43-63	
21882223-7	2012	The functional expression of osteoblast in alkaline phosphatase (ALP) activity was significantly decreased by CoCl(2) and inhibited when treated with DFO.	Deferoxamine	150-153	alkaline phosphatase, placental	Homo sapiens	65-68	
18375202-4	2008	In BMP2-treated MSCs, desferrioxamine levels of 15 microMu were found to increase alkaline phosphatase (ALP) activity and calcium deposition, which were the markers of osteoblastic differentiation.	Deferoxamine	22-37	alkaline phosphatase, placental	Homo sapiens	82-102	
18375202-4	2008	In BMP2-treated MSCs, desferrioxamine levels of 15 microMu were found to increase alkaline phosphatase (ALP) activity and calcium deposition, which were the markers of osteoblastic differentiation.	Deferoxamine	22-37	alkaline phosphatase, placental	Homo sapiens	104-107	
18375202-6	2008	Knockdown of beta-catenin by RNA interference eliminates this positive effect of desferrioxamine on ALP activity.	Deferoxamine	81-96	alkaline phosphatase, placental	Homo sapiens	100-103